drugset
drugset / Trial / NCT01297400

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

NCT01297400 ↗

Phase 2 Recruiting 60 enrolled Skingenix, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Timeline

Start
2022-03-11
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MW-III Unknown — Topical
Comparator Silver Sulfadiazine Small molecule — Topical

Indications

No indication recorded.